TargetBeta
CYP3A4
cytochrome P450 family 3 subfamily A member 4 · also CYP3A3 · Cytochrome P450 family 3
1 program in company-led studies act on CYP3A4, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Ritonavirrule | Boehringer Ingelheim | phase 4 | 1742 running | CYP3A43, CYP3A5, CYP3A7 | ChEMBL |
Conditions their studies are in
- Acquired Immunodeficiency Syndrome, 1 program
- COVID-19, 1 program
- Hepatitis C, 1 program
- Hepatitis C, Chronic, 1 program
- HIV Infections, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.